AMT-676 in Patients With Advanced Solid Tumors

Patients must be willing and able to sign the ICF, and to adhere to the study visit Schedule and other protocol requirements.

Age ≥18 years (at the time consent is obtained).

Patients with pathologically confirmed unresectable advanced solid tumor. Preferred tumor types include colorectal cancer, gastric cancer, esophageal adenocarcinoma, cholangiocarcinoma, pancreatic ductal cancers, and neuroendocrine tumors.

Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy.